Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Herceptin|DRUG: Herceptin|DEVICE: Single-Use Injection Device|DEVICE: Single-Use Injection Device
Sponsor: Hoffmann-La Roche